- Price
- $219.00
- Day
- -0.60%
- Mkt Cap
- $29.30B
- 52W Range
- $197.81 – $495.55
- Volume
- 3.04M
- Beta
- 0.27
Find a company by name or ticker and open its page
Breaking news, press releases, and analyst updates.
Most recent articles and analysis covering this company.
LOS ANGELES, Aug. 4, 2026 /PRNewswire/ -- Schall, Brown & Schwartz LLP ("SBS"), a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Alnylam Pharmaceuticals, Inc. ("Alnylam" or "the Company") (NASDAQ: ALNY) for violations of the securities laws. INVESTIGATION DETAILS: The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Read full article
Bragar Eagel & Squire, P.C. Litigation Partners Brandon Walker and Melissa Fortunato Encourage Investors Who Suffered Losses In Alnylam (ALNY) To Contact Them Directly To Discuss Their Options
Read full article
LOS ANGELES, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Glancy Prongay Wolke & Rotter LLP, a leading national shareholder rights law firm, continues its investigation on behalf of Alnylam Pharmaceuticals, Inc. (“Alnylam” or the “Company”) (NASDAQ: ALNY) investors concerning the Company's possible violations of the federal securities laws. IF YOU ARE AN INVESTOR WHO LOST MONEY ON ALNYLAM PHARMACEUTICALS, INC.
Read full article
BENSALEM, Pa., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Law Offices of Howard G. Smith continues its investigation on behalf of Alnylam Pharmaceuticals, Inc. (“Alnylam” or the “Company”) (NASDAQ: ALNY) investors concerning the Company's possible violations of federal securities laws.
Read full article
[url="]Schall, Brown and Schwartz[/url] LLP (âSBSâ), a national shareholder rights litigation firm, announces that it is investigating claims on behalf of inv
Read full article
LOS ANGELES--(BUSINESS WIRE)---- $ALNY--ALNY Investors Have Opportunity to Join Alnylam Pharmaceuticals, Inc. Fraud Investigation with SBS Law.
Read full article
LOS ANGELES, Aug. 03, 2026 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz continues its investigation of Alnylam Pharmaceuticals, Inc. (“Alnylam” or the “Company”) (NASDAQ: ALNY) on behalf of investors concerning the Company's possible violations of federal securities laws.
Read full article
Alnylam stock plunges after Q2 earnings and revenue miss estimates, while a cut to 2026 product sales guidance overshadows record quarterly Amvuttra sales.
Read full article
NEW YORK, July 31, 2026 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP is investigating potential claims against Alnylam Pharmaceuticals, Inc. (“Alnylam” or the “Company”) (NASDAQ: ALNY). The investigation concerns whether the Company and/or members of its senior management may have violated federal securities laws or engaged in other unlawful business practices.
Read full article
Alnylam Pharmaceuticals, Inc. (ALNY) Q2 2026 Earnings Call Transcript
Read full article
The headline numbers for Alnylam (ALNY) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Read full article
Alnylam Pharmaceuticals (ALNY) came out with quarterly earnings of $1.84 per share, missing the Zacks Consensus Estimate of $2.05 per share. This compares to earnings of $0.32 per share a year ago.
Read full article